Novel Approach to Proficiency Testing Highlights Key Practice Variations in Cancer Biomarker Delivery

Author:

Bisson Kassandra R.12,Won Jennifer R.1,Beharry Andrea3,Carter Michael D.4ORCID,Dudani Shaan5ORCID,Garratt John G.1,Loree Jonathan M.6ORCID,Snow Stephanie7ORCID,Yip Stephen8,Sheffield Brandon S.13

Affiliation:

1. Canadian Pathology Quality Assurance-Assurance Qualité Canadienne en Pathologie (CPQA-AQCP), Richmond, BC V6Y 1K3, Canada

2. Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada

3. Department of Laboratory Medicine, William Osler Health System, Brampton, ON L6R 3J7, Canada

4. Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada

5. Division of Medical Oncology & Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada

6. Division of Medical Oncology, BC Cancer, Vancouver Centre, Vancouver, BC V5Z 4E6, Canada

7. Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 2Y9, Canada

8. Department of Pathology and Laboratory Medicine, University of British Colombia, Vancouver, BC V6T 2B5, Canada

Abstract

Biomarkers are fundamental to modern oncology practice, forming a close link to pathology practice. Pathology results must be accurate, timely, comprehensive, and comprehendible. External proficiency testing is a key tool in maintaining biomarker quality. Here, we demonstrate the feasibility and utility of a novel end-to-end proficiency testing exercise exploring accuracy, turnaround time, and communication. Challenge specimens were made using resected colon cancer tissue, each paired with a fictional clinical vignette, and distributed to participants who were asked to provide all molecular testing required and return a final report for each case upon completion. Reports were redistributed to an assessor team including medical oncologists, each of whom was asked to recommend a systemic therapy based on each lab’s biomarker report. Participants were graded based on their ability to guide oncologists to the correct treatment. Eight laboratories participated. Three laboratories were found to have suboptimal results, two leading oncologists to incorrect therapeutic prescriptions, and one withdrawn. Turnaround time ranged from 6 to 86 days (median 24). Substantial qualitative reporting differences were identified. This study demonstrates the feasibility of end-to-end proficiency testing. The approach provides considerable value beyond analytic accuracy, including specimen management, turnaround time, and communication of results. Results suggest that reporting differences may lead to treatment disparities. This style of quality assurance will help reinforce good practices critical to the delivery of precision cancer care.

Funder

Pfizer Canada

Astra Zeneca Global

Amgen Canada

Publisher

MDPI AG

Subject

General Medicine

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3